| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18429492 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 112 journal articles in the PubMed database | Email to a friend | | |
| Annecke K, Schmitt M, Euler U, et al.
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. [Journal Article]
Adv Clin Chem 2008.:31-45.
Abstract | Full Citation | Find Related Articles | | Harbeck N, Kates RE, Gauger K, et al.
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. [Journal Article, Review]
Thromb Haemost 2004 Mar; 91(3):450-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Harbeck N, Schmitt M, Kates RE, et al.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. [Journal Article, Review]
Clin Breast Cancer 2002 Aug; 3(3):196-200.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Harbeck N, Kates RE, Look MP, et al.
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). [Journal Article]
Cancer Res 2002 Aug 15; 62(16):4617-22.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Jänicke F, Prechtl A, Thomssen C, et al.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Natl Cancer Inst 2001 Jun 20; 93(12):913-20.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Harbeck N, Kates RE, Schmitt M, et al.
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. [Journal Article, Review]
Clin Breast Cancer 2004 Dec; 5(5):348-52.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Harbeck N, Kates RE, Schmitt M
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. [Journal Article]
J Clin Oncol 2002 Feb 15; 20(4):1000-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Harbeck N, Thomssen C
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast] [Journal Article]
Zentralbl Gynakol 2003 Sep; 125(9):362-7.
Abstract | Full Citation | Find Related Articles | | Foekens JA, Peters HA, Look MP, et al.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. [Journal Article]
Cancer Res 2000 Feb 1; 60(3):636-43.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
